• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Clinical Development
    • Biologics
  • Fierce 50
    • Special Report
    • Awards Gala
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending T
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Clinical Development
    • Biologics
  • Fierce 50
    • Special Report
    • Awards Gala
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Chipscreen Bioscience

liver disease fibrosis NASH NAFLD cancer cirrhosis liver
Biotech

Chinese biotech's MASH drug reduces liver fat in phase 2 trial

Chipscreen Biosciences' MASH candidate reduced patients' liver fat levels, adding further momentum to drugs aimed at the condition.
Max Bayer Mar 18, 2024 11:07am
china chinese Asia

Chipscreen bags Chinese rights to Biocytogen's Keytruda killer

Feb 27, 2023 10:30am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2024 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings